WARSAW, Ind., Sept. 8, 2015 (GLOBE NEWSWIRE) — Nextremity Solutions, Inc., a pure-play foot and ankle company, recently received 510(k) approval by the Food & Drug Administration to market its upcoming ArcusTM Staple System.
“We are excited about the recent 510(k) approval of Nextremity’s new ArcusTM Staple System. The unique design of our new staple generates excellent compression and is indicated for use throughout the foot and ankle. Our testing has shown that the ArcusTM Staple performs better at maintaining compression over time when compared to the competition. We look forward to the first implantations later this year,” said Director of Product Development, Ryan Schlotterback.
Rod K. Mayer, President of Nextremity Solutions said, “I’m extremely proud of the hard work our product development team has put into this product line. By working closely with our surgeon partners, we have developed a truly unique staple that will provide for more stable fixations in foot and ankle deformity correction, as well as trauma applications and other uses. We look forward to getting this product into the marketplace.”
The Nextremity Solutions Arcus™ Staple System is indicated for fixation of bone fractures, bone reconstruction, ligament, soft tissue and tendon. This includes, fixation of bone fragments or small bones fractures, as well as fracture management in the foot and hand. An application for a CE mark is pending.
About Nextremity Solutions, Inc.
Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.